No Data
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Optimistic Outlook for Axsome Therapeutics' Auvelity Amid Steady Prescription Growth
Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
Positive Buy Recommendation for Axsome Therapeutics Driven by Promising AXS-05 Efficacy in Alzheimer's Agitation
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115